Anticancer
The process will pit breast cancer treatment competitors Kisqali and Verzenio against each other as CMS develops pricing offers.
Multiple Chinese biotechs are seeking to raise new funds through IPOs on the Hong Kong and Beijing stock exchanges to support international clinical trials for their first-in-class molecules.
The company announced Phase II data and plans for its registrational Phase III trial as CEO Mark Erlander and chief financial officer James Levine left the company.
The Belgian biotech is closing its CAR-T division and pivoting to a new de-risked business development model, with the blessing of long-term investor, Gilead.
Fund IV exclusively targets company creation and early-stage investing across the UK and the US.
The Phase I/II study’s trial page was updated to say it was no longer recruiting patients after recruiting only 23 of the originally planned 260.
The company is getting ready for multiple cancer drug launches, potentially including anti-PD-L1/VEGF pumitamig. Chief commercial officer Annemarie Hanekamp spoke to Scrip.
Companies requiring follow-on financing were particularly hit in 2025, but the first signs of ‘pension power’ has given the UK sector hope of more investment.
Deal Snapshot: BMS is casting a broad net in oncology as it looks to replace its aging blockbuster Opdivo with a variety of novel cancer therapies.
The company announced that the Phase III ROSELLA trial in platinum-resistant ovarian cancer met its overall survival primary endpoint.
While a record number of China-originated first-in-class drugs were approved domestically in 2025, only one has so far entered clinical development overseas with its originator as the sole sponsor. But more progress is expected this year.
J&J will lean on its four-drug multiple myeloma franchise to drive oncology growth during the rest of the decade, but top-seller Darzalex is facing US and EU patent expiration.
Two familiar heavyweights of the obesity field return for another match, while four smaller companies are tipped to bring their own blockbusters to market, new data from Evaluate Pharma show.
The Phase II data for intismeran autogene in melanoma were mostly incremental, but the program’s continued success is a cornerstone of Moderna’s breakeven strategy.
Clinical Data Readout: A mixed Phase III study in relapsed/refractory DLBCL complicates AbbVie and Genmab’s bid to expand Epkinly beyond its accelerated approval.
Patrick Soon-Shiong said that lymphodepletion may end up being proven unnecessary, especially with some of the newer cell therapy approaches.
Clinical Data Readout: J&J’s BCMA-targeting bispecific antibody Tecvayli reduced the risk of disease progression or death by 71% in patients with relapsed/refractory multiple myeloma who have received one to three prior lines of therapy.
In a presentation at the J.P. Morgan Healthcare Conference and an interview with Scrip, CEO Amy Burroughs laid out Terns’ plans for its allosteric BCR-ABL inhibitor in CML.
The biotech is expecting its first Phase III readout in early 2026 amid talk that Merck may be ready to acquire its novel cancer therapies for $28bn or more.
The company is setting aside potentially more than $5bn to license RemeGen’s RC148, after similar deals by companies like Merck, Pfizer and Bristol Myers Squibb.